The Flamma Group, a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry, and CDMO of New Chemical Entities (NCEs) and late-stage intermediates, is investing $200 million over the next three years as the company continues to respond to market demand.
 
Flamma will invest in the following projects:
• Revamping and improving the Bulciago, Italy site that was acquired in 2022.
• Completion of a new GMP facility at its Dalian, China location. Flamma Honkai will increase small molecule API/NCE capacity to initially 400 m³ and then ultimately to 800 m³.
• The addition of new technologies across its sites in Italy, China and the U.S.
   o Including growing existing flow chemistry capabilities at Flamma Italy 
   o Build out of an API clean room at Flamma USA
   o Additional improvements to HPAPI capabilities at Flamma USA
• Additional improvements will be made at Flamma’s two other Italian facilities, Chignolo and Isso. These site improvements include upgrades to the existing analytical services offered as well as the installation of new equipment, including reactors, filter dryers, distillation units. To harness the power of renewable energy, Flamma will be adding solar panels as well.
 
In consideration of the current geo-political environment, Flamma is proactively securing customers supply chains with the ability to transfer projects from China (Flamma Honkai) to Italy (specifically its Bulciago site). Flamma offers the market a unique value proposition where one can still work in China but also have the security to also work simultaneously in Italy. 
 
Alternatively, work can be done in China but can be internally transferred to Italy if needed. In addition, the Chinese domestic market will grow dramatically in the coming years and Flamma Honkai’s facilities in China can be the right choice for developing and producing APIs in China for its domestic market.
 
Dr. Gianpaolo Negrisoli, Chief Executive Officer of Flamma, said, “Flamma will continue to reinvest in itself to provide further flexibility among all of our sites.”
 
Flamma Bulciago has reactor capacities up to 25,000 L with an average reactor size of 12,000 L. This GMP site is an attractive option for those companies looking for additional capacities in Europe. The combination of Bulciago along with Chignolo and Isso provides Flamma with 900 m³ of small molecule manufacturing capacity in Italy.
 
The continued development of Flamma USA near Philadelphia, PA provides innovator companies the flexibility to begin early stage small molecule projects in the U.S. and then consider using the rest of the Flamma Group for its needs as the project grows. Since Flamma can often make the necessary RSMs, the security of supply is strengthened by Flamma’s ability to provide internal backup to manufacturing.
 
“Our future is very bright. We are aware of customer sensitivity about their supply chain. Years of work and huge investments have been placed into their molecules. This cannot be jeopardized by looking for the lowest price or underestimating the risks of a weak supply chain. We have manufacturing facilities with different characteristics to meet customer needs. This includes capacity and technologies along with a very skilled and committed team that works hard to be a long-term partner,” said Negrisoli.